APA (7th ed.) Citation

Papp, K., Kaufmann, R., Thaçi, D., Hu, C., Sutherland, D., & Rohane, P. (2013). Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: Results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. Journal of the European Academy of Dermatology and Venereology, 27(3), e376-e383. https://doi.org/10.1111/j.1468-3083.2012.04716.x

Chicago Style (17th ed.) Citation

Papp, K.A, R. Kaufmann, D. Thaçi, C. Hu, D. Sutherland, and P. Rohane. "Efficacy and Safety of Apremilast in Subjects with Moderate to Severe Plaque Psoriasis: Results from a Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-comparison Study." Journal of the European Academy of Dermatology and Venereology 27, no. 3 (2013): e376-e383. https://doi.org/10.1111/j.1468-3083.2012.04716.x.

MLA (9th ed.) Citation

Papp, K.A, et al. "Efficacy and Safety of Apremilast in Subjects with Moderate to Severe Plaque Psoriasis: Results from a Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-comparison Study." Journal of the European Academy of Dermatology and Venereology, vol. 27, no. 3, 2013, pp. e376-e383, https://doi.org/10.1111/j.1468-3083.2012.04716.x.